Lecanemab in Early Alzheimer’s Disease
Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was...
Publications
6 shownToward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide ...
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Abstract Objective Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods Am...
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
We found that autosomal dominant Alzheimer's disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of Alzheimer's disease, b...
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Abstract During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker resear...
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease
Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomark...
Frequent Co-Authors
Researcher Info
- h-index
- 6
- Publications
- 6
- Citations
- 19,037
- Institution
- Autism Research Institute
External Links
Impact Metrics
h-index
6
h-index: Number of publications with at least h citations each.